pioglitazone has been researched along with Electron Transport Chain Deficiencies, Mitochondrial in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Differentiated SH-SY5Y neuroblastoma cells were exposed to the PD relevant mitochondrial complex 1 inhibitor 1-methyl-4-phenylpyridinium iodide (MPP+)." | 3.83 | Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis. ( Carroll, CB; Eastwood, J; Hanemann, CO; McCorry, K; Zajicek, JP; Zeissler, ML, 2016) |
| "Pioglitazone treatment restored in vivo muscle oxidative capacity in diabetic rats to the level of lean controls." | 1.42 | Pioglitazone treatment restores in vivo muscle oxidative capacity in a rat model of diabetes. ( Ciapaite, J; Houten, SM; Nicolay, K; Prompers, JJ; van den Broek, NM; Wessels, B, 2015) |
| "Treatment with Pioglitazone prevented the increase in the number of activated microglia and no difference was observed between sham and Pioglitazone-treated animals." | 1.37 | Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. ( Bing, G; Gao, J; Liu, M; Pauly, JR; Readnower, R; Sauerbeck, A; Sullivan, PG, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wassef, MAE | 1 |
| Tork, OM | 1 |
| Rashed, LA | 1 |
| Ibrahim, W | 1 |
| Morsi, H | 1 |
| Rabie, DMM | 1 |
| Wessels, B | 1 |
| Ciapaite, J | 1 |
| van den Broek, NM | 1 |
| Houten, SM | 1 |
| Nicolay, K | 1 |
| Prompers, JJ | 1 |
| Zeissler, ML | 1 |
| Eastwood, J | 1 |
| McCorry, K | 1 |
| Hanemann, CO | 1 |
| Zajicek, JP | 1 |
| Carroll, CB | 1 |
| Sauerbeck, A | 1 |
| Gao, J | 1 |
| Readnower, R | 1 |
| Liu, M | 1 |
| Pauly, JR | 1 |
| Bing, G | 1 |
| Sullivan, PG | 1 |
4 other studies available for pioglitazone and Electron Transport Chain Deficiencies, Mitochondrial
| Article | Year |
|---|---|
Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4.
Topics: Animals; Cardiolipins; Diabetic Cardiomyopathies; Disease Models, Animal; Exenatide; Hypoglycemic Ag | 2018 |
Pioglitazone treatment restores in vivo muscle oxidative capacity in a rat model of diabetes.
Topics: Animals; Biomarkers; Carnitine; Diabetes Mellitus, Type 2; Hypertriglyceridemia; Hypoglycemic Agents | 2015 |
Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis.
Topics: 1-Methyl-4-phenylpyridinium; Cell Line, Tumor; Dronabinol; Humans; Mitochondria; Mitochondrial Disea | 2016 |
Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury.
Topics: Analysis of Variance; Animals; Brain Injuries; CD11b Antigen; Cerebral Cortex; Cognition Disorders; | 2011 |